John McHutchison
Directeur/Bestuurslid bij ASSEMBLY BIOSCIENCES, INC.
Vermogen: 289 426 $ op 31-05-2023
Profiel
Dr. John G.
McHutchison, MD, is a President & Chief Executive Officer at Velia, Inc. and a Member at The Royal Australasian College of Physicians.
He is on the Board of Directors at Tune Therapeutics, Inc., Evox Therapeutics Ltd.
and Assembly Biosciences, Inc. Dr. McHutchison was previously employed as a Co-Founder by Actio Biosciences, Inc., an Independent Director by Metacrine, Inc., a Chief Scientific Officer, Head-R&D by Gilead Sciences, Inc., an Associate Director by Duke Clinical Research Institute, a Professor by Duke University Medical Center, a Medical Director-Liver Transplantation by Scripps Clinic & Research Foundation, and an Assistant Professor by University of Southern California.
He also served on the board at Oxford BioTherapeutics Ltd.
He received his undergraduate degree from the University of Melbourne and a doctorate degree from the University of Melbourne.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 29-05-2024 | 19 104 ( 0.35% ) | 289 426 $ | 31-05-2024 | |
METACRINE INC
-.--% | 03-02-2023 | 0 ( -.--% ) | - $ | 31-05-2023 |
Actieve functies van John McHutchison
| Bedrijven | Functie | Begin |
|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Directeur/Bestuurslid | 06-08-2019 |
| The Royal Australasian College of Physicians | Corporate Officer/Principal | - |
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Directeur/Bestuurslid | 18-01-2021 |
Tune Therapeutics, Inc.
 Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | Directeur/Bestuurslid | 17-01-2023 |
Velia, Inc.
 Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | Algemeen Directeur | 19-07-2023 |
Eerdere bekende functies van John McHutchison
| Bedrijven | Functie | Einde |
|---|---|---|
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Directeur/Bestuurslid | 24-04-2023 |
| METACRINE, INC. | Directeur/Bestuurslid | 23-03-2023 |
| GILEAD SCIENCES, INC. | Hoofd Techniek/Wetenschap/O&O | 02-08-2019 |
Actio Biosciences, Inc.
 Actio Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Actio Biosciences, Inc. is an American precision medicine company that focuses on developing new therapeutics for rare and common diseases by targeting shared genetics. Actio Biosciences was founded in October 2021 and is based in an undisclosed location. The company applies its expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward potent and precisely targeted therapeutics. The company is led by leaders in genetics and drug development and backed by top healthcare investors. | Oprichter | - |
| ░░░░░░░ ░░░░░░ ░░░░░ ░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Opleiding van John McHutchison
| University of Melbourne | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| METACRINE, INC. | Health Technology |
| Bedrijven in privébezit | 8 |
|---|---|
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Duke Clinical Research Institute
 Duke Clinical Research Institute Pharmaceuticals: OtherHealth Technology Duke Clinical Research Institute manufactures medical and botanical products. It offers specialized patient databases and clinical and operational expertise. The firm accelerates the development of therapies, diagnostics, and medical devices to humans. The company was founded in 1969 and is headquartered in Durham, NC. | Health Technology |
| Scripps Clinic & Research Foundation | |
| The Royal Australasian College of Physicians | |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | Health Technology |
Velia, Inc.
Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | Technology Services |
Actio Biosciences, Inc.
Actio Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Actio Biosciences, Inc. is an American precision medicine company that focuses on developing new therapeutics for rare and common diseases by targeting shared genetics. Actio Biosciences was founded in October 2021 and is based in an undisclosed location. The company applies its expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward potent and precisely targeted therapeutics. The company is led by leaders in genetics and drug development and backed by top healthcare investors. | Health Technology |
